Distribution of misonidazole adducts in 9L gliosarcoma tumors and spheroids: implications for oxygen distribution
- PMID: 1617656
Distribution of misonidazole adducts in 9L gliosarcoma tumors and spheroids: implications for oxygen distribution
Abstract
The 9L rat gliosarcoma is a widely used experimental brain tumor which has an unusual radiation response. The radiation sensitivity of cells in subcutaneous tumors has been shown to be intermediate between those of aerobic and hypoxic 9L cells in vitro, and cells in spheroids and intracranial tumors appear to be as sensitive as fully aerobic cells. The hypoxic marker misonidazole was used to investigate the distribution of oxygen in these 9L systems. In vitro calibration of binding of [3H]-misonidazole as a function of oxygen concentration demonstrated an inverse relationship similar to those of several other experimental tumors. In autoradiograms of sections from tumors labeled in vivo the grain density rose gradually from the periphery of the tumor to the center. Over millimeter distances the distribution of grains was remarkably uniform, in contrast to the substantial variation reported for several other tumors. The grain density as a function of distance from capillaries was essentially constant. Several interpretations of this result are possible, including the postulate that intermittent blood flow occurs in all 9L tumor capillaries, which results in the majority of the binding of misonidazole occurring during the periods of transient hypoxia. Cells adjacent to the necrotic center in 9L spheroids and the rare necrotic regions in tumors appeared to be severely hypoxic, based on the quantity of misonidazole they bound. Spheroid "cure" experiments demonstrated that these cells were not clonogenic.
Similar articles
-
Further characterization of 4-bromomisonidazole as a potential detector of hypoxic cells.Radiat Res. 1985 Apr;102(1):76-85. Radiat Res. 1985. PMID: 3983371
-
Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.Cancer Res. 2000 May 1;60(9):2449-57. Cancer Res. 2000. PMID: 10811123
-
2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors.Cancer Res. 1996 Jan 15;56(2):405-11. Cancer Res. 1996. PMID: 8542599
-
Hypoxic fraction and binding of misonidazole in EMT6/Ed multicellular tumor spheroids.Radiat Res. 1985 Jul;103(1):89-97. Radiat Res. 1985. PMID: 4070561
-
Misonidazole and other hypoxia markers: metabolism and applications.Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1195-202. doi: 10.1016/0360-3016(86)90257-9. Int J Radiat Oncol Biol Phys. 1986. PMID: 3528089 Review.
Cited by
-
Variable presence of hypoxia in M006 human glioma spheroids and in spheroids and xenografts of clonally derived sublines.Br J Cancer. 1998 Nov;78(10):1261-8. doi: 10.1038/bjc.1998.669. Br J Cancer. 1998. PMID: 9823964 Free PMC article.
-
Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs).Cancer Metastasis Rev. 1993 Jun;12(2):135-51. doi: 10.1007/BF00689806. Cancer Metastasis Rev. 1993. PMID: 8375017 Review.
-
Pimonidazole binding in C6 rat brain glioma: relation with lipid droplet detection.Br J Cancer. 2003 May 6;88(9):1439-44. doi: 10.1038/sj.bjc.6600837. Br J Cancer. 2003. PMID: 12778075 Free PMC article.
-
In vivo observation of intracellular oximetry in perfluorocarbon-labeled glioma cells and chemotherapeutic response in the CNS using fluorine-19 MRI.Magn Reson Med. 2010 Nov;64(5):1252-9. doi: 10.1002/mrm.22506. Epub 2010 Sep 21. Magn Reson Med. 2010. PMID: 20860007 Free PMC article.
-
The novel fluorinated 2-nitroimidazole hypoxia probe SR-4554: reductive metabolism and semiquantitative localisation in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopic analysis.Br J Cancer. 1995 Aug;72(2):312-8. doi: 10.1038/bjc.1995.330. Br J Cancer. 1995. PMID: 7640211 Free PMC article.